Cure TV

In an interview, Dr. Nina Shah of UCSF Helen Diller Family Comprehensive Cancer Center discusses how she changed her perspective on finding a cure for myeloma and what her goals are when it comes to treating her patients.

In an interview, Dr. Andrew Yee of Massachusetts General Hospital discusses how a multiple myeloma diagnosis affects a patient’s life and how hopeful he is about helping them lead normal lives.

In an interview, Dr. Nina Shah of UCSF Helen Diller Family Comprehensive Cancer Center explains what a myeloma millennial, or ‘myelennial,’ is, and how recent advances in multiple myeloma treatments inspired the term.

The term “survivor” is often used to describe people who have successfully completed their cancer treatments, but Sonia Su feels like it doesn’t quite capture the complexity of what it means to be in remission.

Although “social distancing” has become a common term used to describe the safe distance people keep from others to avoid contracting COVID-19, stage 1 ovarian cancer survivor and teacher Brenda Kowalski reminds patients who may be starting out on their cancer journey that it’s important to not “socially distance” yourself from friends when you need support.

Nearly one year ago to the day, 24-year-old Nina Luker was completely blindsided by a diagnosis of non-Hodgkin lymphoma. But after powering through treatments in the thick of the COVID-19 pandemic, Luker is now cancer-free and offering advice to those who may be looking for ways to help their loved ones through difficult times of their own.

While it is important to educate oneself after receiving a diagnosis of cancer, it’s also critical to know when to step away and find a balance between cancer and life, according to Diane Zipursky-Quale.

Positive results from the phase 3 CLEAR clinical trial, presented at the 2021 ASCO Genitourinary Cancers Symposium, are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma (RCC), says the study’s lead author, Dr. Robert J. Motzer.

Breast cancer survivor and Evofem Biosciences founder and CEO Saundra Pelletier shares her thoughts on a new hormone-free contraceptive gel that could improve sexual quality of life in patients with cancer.

For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team.

Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.

Diane Powis spent more than 10 months bouncing from one doctor to the next before finally being “blindsided by” a diagnosis of stage 3 ovarian cancer. But as her initial feelings of isolation and fear wore off, Powis soon learned that she wasn’t alone – and that help and information were out there.

While the threat of COVID-19 still looms across the country, the risks of delaying cancer screenings – or active surveillance for those patients who are currently in treatment – could be greater than people think, says City of Hope’s Dr. Ravi Salgia.

Clinical trials may seem scary and challenging for patients with cancer, but in reality, they don’t have to be. Here is how talking to former patients on clinical trials can help.

In an interview, Dr. Matthew Davids of the Dana-Farber Cancer Institute discusses the future of CAR T-Cell therapy in the treatment of younger patients with chronic lymphocytic leukemia.

Caregiving for a patient with cancer is an ongoing journey that also requires the caregiver to learn along the way. One couple discusses that process and more.

In an interview with CURE®, expert Martha Raymond explains the importance of clinical trials during the COVID-19 pandemic and how clinicians must find a way to help ease patients anxieties as they return to the clinic.

In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute discussed why it’s important for patients with CLL, regardless of their treatment plans, to keep up on vaccinations and maintain a regular cancer screening schedule.

Janice and Rex Cowden sat down for an interview to discuss how to navigate a cancer diagnosis as a couple, and that communication is not only the key to a better cancer journey but a better marriage.

In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute in Boston discussed how the addition of Copiktra to a three-drug chemotherapy combination improved outcomes in patients with CLL, with more than half achieving complete remission.

In an interview with CURE®, Dr. Lawrence An discusses how expressive writing can be a tool to reduce stress in patients with cancer.

It's easy to get lost in the statistics of survivorship, but it's important for newly diagnosed patients with cancer to remember that they are not a statistic.

In a recent trial, the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal women with lymph node-positive, HR-positive, HER2-negative breast cancer.

Street artist James Cochran gives CURE® an inside look at his newest project: a piece of art he created by applying 50,000 small dots of paint to a canvas using a lab pipette. It will be displayed in the Institute of Cancer Research’s Centre for Cancer Drug Discovery as a symbol of the creativity and commitment of the scientists who work every day to eradicate cancer.

In an interview with CURE®, a Waldenstrom’s macroglobulinemia expert discusses the long-term benefits of the targeted combination of Imbruvica and Rituxan.

Imbruvica treatment in patients with chronic lymphocytic leukemia whose disease expressed a certain mutation elicited sustained efficacy over a median follow-up of four years, according to data from a long-term analysis.

In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.

In an interview with CURE®, lead study investigator Dr. John Mascarenhas discusses what the results of the phase 2 IMbark study could mean for the future of patients with myelofibrosis.

The research process for pancreatic cancer is long and difficult, but a new method of clinical trials is looking to adapt to a growing field and find ways to speed up research without losing efficiency.